Your browser is no longer supported. Please, upgrade your browser.
Settings
ARRY Array BioPharma Inc. daily Stock Chart
ARRY [NASD]
Array BioPharma Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own0.20% Shs Outstand193.48M Perf Week-10.36%
Market Cap2.14B Forward P/E- EPS next Y-0.39 Insider Trans-16.92% Shs Float191.85M Perf Month-3.40%
Income-116.80M PEG- EPS next Q-0.22 Inst Own94.90% Short Float12.19% Perf Quarter42.05%
Sales150.90M P/S14.21 EPS this Y-10.20% Inst Trans3.94% Short Ratio5.67 Perf Half Y32.69%
Book/sh0.07 P/B158.29 EPS next Y60.60% ROA-48.00% Target Price15.00 Perf Year68.39%
Cash/sh1.21 P/C9.15 EPS next 5Y10.00% ROE- 52W Range5.36 - 13.40 Perf YTD26.05%
Dividend- P/FCF- EPS past 5Y-16.50% ROI-71.10% 52W High-17.31% Beta2.00
Dividend %- Quick Ratio3.90 Sales past 5Y12.10% Gross Margin76.50% 52W Low106.72% ATR0.43
Employees209 Current Ratio3.90 Sales Q/Q-21.80% Oper. Margin-68.60% RSI (14)40.09 Volatility3.66% 3.31%
OptionableYes Debt/Eq0.00 EPS Q/Q0.60% Profit Margin-77.40% Rel Volume0.43 Prev Close11.34
ShortableYes LT Debt/Eq11.44 EarningsOct 31 BMO Payout- Avg Volume4.13M Price11.08
Recom1.80 SMA20-8.07% SMA503.36% SMA20015.86% Volume1,788,937 Change-2.29%
Sep-11-17Reiterated Stifel Buy $13 → $15
May-03-17Upgrade JP Morgan Neutral → Overweight
Feb-03-17Reiterated Stifel Buy $8 → $13
Feb-03-17Downgrade JP Morgan Overweight → Neutral
Jan-30-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-26-16Reiterated Piper Jaffray Overweight $7 → $10
Sep-26-16Reiterated Leerink Partners Outperform $6 → $9
Jan-26-15Reiterated Stifel Buy $6 → $9
Aug-09-13Reiterated Stifel Buy $7 → $8
Jul-23-10Upgrade UBS Neutral → Buy $4.25
Apr-22-10Downgrade UBS Buy → Neutral
Nov-05-09Upgrade UBS Neutral → Buy
Sep-08-09Downgrade UBS Buy → Neutral
Sep-04-09Downgrade Robert W. Baird Outperform → Neutral $10 → $3
Sep-04-09Downgrade Leerink Swann Outperform → Mkt Perform $6 → $2
Sep-04-09Downgrade Boenning & Scattergood Outperform → Neutral
Jun-17-09Initiated Boenning & Scattergood Outperform $6
May-07-08Reiterated Rodman & Renshaw Mkt Outperform $18 → $15
Feb-07-08Initiated William Blair Outperform
Dec-20-07Reiterated Collins Stewart Buy $17 → $16
Oct-18-17 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Spectrum Pharmaceuticals ACCESSWIRE
Oct-09-17 11:16AM  ETFs with exposure to Array BioPharma, Inc. : October 9, 2017 Capital Cube
08:03AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Oct-04-17 08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Oct-02-17 08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Sep-29-17 08:04AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Sep-28-17 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Horizon Pharma ACCESSWIRE
Sep-26-17 08:04AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Sep-20-17 07:07PM  Cramer's lightning round: I like Altria Group, but it's n... CNBC Videos
Sep-19-17 10:00AM  Array BioPharma To Present At The 2017 Cantor Fitzgerald Global Healthcare Conference PR Newswire
09:09AM  Array BioPharma Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares PR Newswire
Sep-15-17 09:24AM  Mirati Skyrockets On Positive Data - Biotech Movers TheStreet.com
08:20AM  Today's Research Reports on Stocks to Watch: Halozyme Therapeutics and Array Biopharma ACCESSWIRE
Sep-14-17 07:17PM  Array BioPharma Announces Pricing of Public Offering of Common Stock PR Newswire
09:53AM  Colorado biotech plans $200 million stock offering American City Business Journals
09:15AM  Array BioPharma Slides on Secondary Offering 24/7 Wall St.
Sep-13-17 05:13PM  Array BioPharma shares slide on secondary offering announcement MarketWatch +5.62%
04:01PM  Array BioPharma Announces Proposed Public Offering of Common Stock PR Newswire
12:08PM  Steven Cohen Dives Into Array BioPharma GuruFocus.com
10:47AM  Array's NDAs for Melanoma Combo Accepted for Review by FDA Zacks
Sep-12-17 09:09AM  Array BioPharma Announces FDA Acceptance For Review Of Binimetinib And Encorafenib New Drug Applications For Patients With Advanced BRAF-mutant Melanoma PR Newswire -5.32%
08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Sep-11-17 08:56PM  ETFs with exposure to Array BioPharma, Inc. : September 12, 2017 Capital Cube
01:30PM  Array BioPharma And Others Shine At The ESMO 2017 Congress Benzinga
08:10AM  Today's Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology ACCESSWIRE
Sep-09-17 09:30AM  Phase 3 COLUMBUS Part 2 Results in BRAF-Mutant Melanoma Presented at European Society for Medical Oncology Congress PR Newswire
Sep-08-17 04:35PM  Array Resumes Trades After Unveiling Data In Colon Cancer Trial Investor's Business Daily +6.91%
04:31PM  Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q4, 2017 By the Numbers : September 8, 2017 Capital Cube
12:58PM  Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress PR Newswire
08:14AM  Array BioPharma Seems to Be in a New Uptrend TheStreet.com
Sep-06-17 03:10PM  What's Behind Array Biopharma Inc.'s 31% Rally in August? Motley Fool
08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Aug-30-17 08:00AM  Array Biopharma To Present BEACON CRC Safety Lead-in And COLUMBUS Part 2 Results At European Society For Medical Oncology Congress (ESMO) PR Newswire
Aug-28-17 02:00PM  Array BioPharma To Present At The 2017 Wells Fargo Healthcare Conference PR Newswire
Aug-24-17 02:58PM  ETFs with exposure to Array BioPharma, Inc. : August 24, 2017 Capital Cube
12:51PM  Harry Boxer: These three biotech stocks are breaking out MarketWatch
08:44AM  Array BioPharma (ARRY) Looks Good: Stock Adds 5.9% in Session Zacks
Aug-23-17 08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit +5.88%
Aug-16-17 02:21PM  Edited Transcript of ARRY earnings conference call or presentation 9-Aug-17 1:00pm GMT Thomson Reuters StreetEvents
01:05PM  3 Big Stock Charts for Wednesday: Amazon.com, Inc. (AMZN), Array Biopharma Inc (ARRY) and Paychex, Inc. (PAYX) InvestorPlace
08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Aug-14-17 05:00PM  Array BioPharma Appoints Curtis Oltmans As General Counsel PR Newswire
02:36PM  Array BioPharma, Inc. :ARRY-US: Earnings Analysis: 2017 By the Numbers : August 14, 2017 Capital Cube
08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma Inc. and 22nd Century Group Inc. ACCESSWIRE
Aug-12-17 08:01AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Aug-11-17 08:01AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
Aug-10-17 08:23AM  Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : August 10, 2017 Capital Cube
08:01AM  IHS Markit Score Update: Drop in demand for ETFs holding Array Biopharma Inc is a negative sign for its shares Markit
Aug-09-17 09:30PM  Array BioPharma reports 4Q loss Associated Press +9.62%
08:02AM  See what the IHS Markit Score report has to say about Array Biopharma Inc. Markit
06:10AM  Investor Network: Array BioPharma Inc. to Host Earnings Call ACCESSWIRE
06:00AM  Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 PR Newswire
Aug-07-17 04:19PM  Here's Why Array BioPharma Inc. Fell 13.7% in July Motley Fool
Aug-04-17 08:15PM  Array BioPharma, Inc. Value Analysis (NASDAQ:ARRY) : August 5, 2017 Capital Cube +8.13%
Aug-03-17 11:49AM  Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017 PR Newswire
Jul-24-17 09:32AM  Array BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : ARRY-US : July 24, 2017 Capital Cube -5.34%
Jul-20-17 11:08AM  New Strong Sell Stocks for July 20th Zacks
Jul-18-17 12:03PM  Colorado biotech makes deal with industry giant American City Business Journals
08:00AM  Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation PR Newswire
Jul-14-17 10:04AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Array BioPharma Inc. Business Wire
Jul-12-17 02:12PM  ETFs with exposure to Array BioPharma, Inc. : July 12, 2017 Capital Cube
Jul-10-17 08:37AM  Implied Volatility Surging for Array BioPharma Inc. (ARRY) Stock Options Zacks
Jul-06-17 06:02PM  Array (ARRY) Submits NDA for Melanoma Combination Therapy Zacks
Jul-05-17 09:50AM  Array BioPharmas New FDA Submissions Enough to Excite Investors? 24/7 Wall St.
08:00AM  Array BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced Melanoma PR Newswire
Jun-27-17 02:54PM  ETFs with exposure to Array BioPharma, Inc. : June 27, 2017 Capital Cube -6.10%
Jun-23-17 08:32AM  Are Options Traders Betting on a Big Move in Array BioPharma (ARRY) Stock? Zacks
Jun-21-17 08:06AM  Array BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : ARRY-US : June 21, 2017 Capital Cube +7.66%
Jun-16-17 03:24PM  ETFs with exposure to Array BioPharma, Inc. : June 16, 2017 Capital Cube
Jun-14-17 10:01AM  Array BioPharma, Inc. :ARRY-US: Earnings Analysis: Q3, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-05-17 05:49PM  Why Array BioPharma Inc. Sank 13.5% in May Motley Fool
Jun-01-17 10:00AM  Array Biopharma To Present At The Goldman Sachs 38th Annual Global Healthcare Conference PR Newswire
08:15AM  Blog Coverage: Array BioPharma and Bristol-Myers Squibb Partner to Investigate Combinations of Binimetinib, Opdivo, and Yervoy in Colorectal Cancer Patients Accesswire
May-31-17 11:13AM  Bristol-Myers Partners Array to Investigate Cancer Candidate Zacks
09:54AM  Biotech Movers: Akari, Array, Amicus TheStreet.com
03:00AM  Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib PR Newswire
May-30-17 06:20PM  Bristol-Myers Hookup Boosts Array BioPharma TheStreet.com
04:14PM  Array BioPharma, Bristol-Myers Squibb to collaborate on cancer drug research American City Business Journals
09:29AM  Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration TheStreet.com
06:59AM  Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration PR Newswire
05:17AM  How Two Biotechs Fell On Cancer Partnerships With Bristol-Myers Investor's Business Daily
May-17-17 08:15AM  Blog Coverage: Mirna Announced Reverse Merger Agreement Accesswire
May-16-17 05:30PM  Edited Transcript of ARRY earnings conference call or presentation 10-May-17 1:00pm GMT Thomson Reuters StreetEvents
May-11-17 08:00AM  Today's Research Reports on Stocks to Watch: Array Biopharma and Verastem Accesswire
May-10-17 01:12PM  Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting Benzinga +20.09%
01:00PM  Here's Why the Market's Overlooking Array Biopharma Inc.'s Earnings Miss Today Motley Fool
08:30AM  Investor Network: Array BioPharma Inc. to Host Earnings Call Accesswire
08:14AM  Array BioPharma reports 3Q loss Associated Press
08:00AM  Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017 PR Newswire
May-09-17 04:01PM  Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma PR Newswire
May-08-17 08:00AM  Array BioPharma Announces Strategic Collaboration with Merck PR Newswire
May-03-17 10:09AM  Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma TheStreet.com +5.03%
08:00AM  Array Biopharma To Report Financial Results For The Third Quarter Of Fiscal 2017 On May 10, 2017 PR Newswire
Apr-27-17 02:00PM  Shalini Sharp Joins Array BioPharma Board of Directors PR Newswire
Apr-20-17 06:22PM  If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss TheStreet.com
Apr-17-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Array Biopharma and ImmunoGen Accesswire
Apr-07-17 08:48AM  Do Options Traders Know Something About Array BioPharma (ARRY) Stock We Don't? Zacks
Mar-22-17 09:58AM  Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down Zacks
09:42AM  Will Array Biopharma's Melanoma Drugs Keep the Stock Soaring? Motley Fool
09:42AM  Will Array Biopharma's Melanoma Drugs Keep the Stock Soaring? at Motley Fool
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEFKOFF KYLEDirectorSep 29Option Exercise10.5845,000476,10051,585Sep 29 06:22 PM
VAN LUNSEN GIL JDirectorSep 29Option Exercise10.5845,000476,10055,260Sep 29 06:23 PM
LEFKOFF KYLEDirectorSep 29Sale12.3138,865478,42812,720Sep 29 06:22 PM
VAN LUNSEN GIL JDirectorSep 29Sale12.3639,928493,51015,332Sep 29 06:23 PM
Haddock JasonCFOAug 14Option Exercise3.7720,00075,40020,000Aug 15 04:31 PM
Saccomano Nicholas ACSOApr 01Option Exercise0.006,875042,061Apr 04 09:42 PM
Sandor VictorChief Medical OfficerApr 01Option Exercise0.007,8120177,428Apr 04 09:43 PM
Squarer RonCEOApr 01Option Exercise0.0018,9060126,369Apr 04 09:43 PM
MOORE JOHN RVP, General CounselApr 01Option Exercise0.006,718046,472Apr 04 09:41 PM
Robbins Andrew RCOOApr 01Option Exercise0.009,843045,851Apr 04 09:42 PM
LEFKOFF KYLEDirectorMar 31Option Exercise3.9945,000179,45051,585Apr 04 09:41 PM
LEFKOFF KYLEDirectorMar 31Sale8.9245,000401,4006,585Apr 04 09:41 PM
BAUM CHARLES MDirectorMar 28Option Exercise3.8725,00096,75030,000Mar 30 05:23 PM
BAUM CHARLES MDirectorMar 28Sale9.2725,000231,7505,000Mar 30 05:23 PM
VAN LUNSEN GIL JDirectorOct 29Option Exercise5.835,00029,15010,260Oct 31 07:46 PM
BAUM CHARLES MDirectorOct 29Option Exercise5.835,00029,1505,000Oct 31 07:15 PM
Fyfe Gwen A.DirectorOct 29Option Exercise5.835,00029,1505,000Oct 31 07:15 PM
LEFKOFF KYLEDirectorOct 29Option Exercise5.835,00029,1508,585Oct 31 07:15 PM
Orwin John ADirectorOct 29Option Exercise5.835,00029,1505,000Oct 31 07:15 PM